Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant vaccines for hepatitis E.

S U Emerson1, R H Purcell

  • 1Molecular Hepatitis and Hepatitis Viruses Sections, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. semerson@niaid.nih.gov

Trends in Molecular Medicine
|October 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limited hepatitis B virus replication space in the chronically hepatitis C virus-infected liver.

Journal of virology·2014
Same author

Serological evidence for a hepatitis e virus-related agent in goats in the United States.

Transboundary and emerging diseases·2012
Same author

Mutational analysis of the hepatitis C virus E1 glycoprotein in retroviral pseudoparticles and cell-culture-derived H77/JFH1 chimeric infectious virus particles.

Journal of viral hepatitis·2009
Same author

Hepatitis E: an emerging awareness of an old disease.

Journal of hepatology·2008
Same author

Characterization of hepatitis E-specific cell-mediated immune response using IFN-gamma ELISPOT assay.

Journal of immunological methods·2007
Same author

A survey of zoonotic pathogens carried by Norway rats in Baltimore, Maryland, USA.

Epidemiology and infection·2007
Same journal

Targeting amino acid metabolism in hepatocellular carcinoma.

Trends in molecular medicine·2026
Same journal

Turning perfusion into repair through ferroptosis blockade.

Trends in molecular medicine·2026
Same journal

CaMKK2: A tumor stress-integration node.

Trends in molecular medicine·2026
Same journal

Precision gene editing: From proof-of-concept to curative therapies.

Trends in molecular medicine·2026
Same journal

Targeting ferroptosis halts graft deterioration in transplantation.

Trends in molecular medicine·2026
Same journal

Amyotrophic lateral sclerosis: A rare but aggressive adult-onset disease.

Trends in molecular medicine·2026
See all related articles

Hepatitis E virus (HEV) causes widespread epidemics and may be zoonotic. A novel vaccine candidate shows promise, protecting macaques and advancing to human clinical trials.

Area of Science:

  • Hepatology
  • Virology
  • Vaccinology

Background:

  • Hepatitis E virus (HEV) is a significant cause of acute hepatitis epidemics, particularly in developing nations.
  • While HEV disease is less common in developed countries, the circulation of avirulent strains and potential zoonotic transmission warrant further investigation.
  • Current understanding suggests a single serotype of HEV exists.

Purpose of the Study:

  • To summarize the current understanding of Hepatitis E virus epidemiology and transmission.
  • To report on the development and preliminary efficacy of a novel HEV vaccine candidate.

Main Methods:

  • Review of existing epidemiological data on HEV.
  • Development of a vaccine using baculovirus-expressed recombinant capsid protein.

Related Experiment Videos

  • Pre-clinical testing in macaque models and Phase I human clinical trials.

    • Main Results:

    • The candidate vaccine demonstrated protective efficacy against HEV in macaque studies.
    • Phase I clinical trials indicated the vaccine was safe and well-tolerated.
    • The vaccine has progressed to Phase II/III clinical trials.

    Conclusions:

    • Hepatitis E virus remains a global health concern with potential zoonotic implications.
    • A recombinant HEV capsid protein vaccine shows significant promise for preventing hepatitis E.
    • Further clinical trials are essential to confirm the vaccine's efficacy and safety in human populations.